PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Rejeski, K.* ; Perez, A.* ; Iacoboni, G.* ; Blumenberg, V.* ; Bücklein, V.L.* ; Völkl, S.* ; Penack, O.* ; Albanyan, O.* ; Stock, S.* ; Müller, F.* ; Karschnia, P.* ; Petrera, A. ; Reid, K.* ; Faramand, R.* ; Davila, M.L.* ; Modi, K.* ; Dean, E.A.* ; Bachmeier, C.* ; von Bergwelt-Baildon, M.* ; Locke, F.L.* ; Bethge, W.* ; Bullinger, L.* ; Mackensen, A.* ; Barba, P.* ; Jain, M.D.* ; Subklewe, M.*

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.

Sci. Adv. 9:eadg3919 (2023)
Postprint DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Prolonged cytopenias after chimeric antigen receptor (CAR) T cell therapy are a significant clinical problem and the underlying pathophysiology remains poorly understood. Here, we investigated how (CAR) T cell expansion dynamics and serum proteomics affect neutrophil recovery phenotypes after CD19-directed CAR T cell therapy. Survival favored patients with "intermittent" neutrophil recovery (e.g., recurrent neutrophil dips) compared to either "quick" or "aplastic" recovery. While intermittent patients displayed increased CAR T cell expansion, aplastic patients exhibited an unfavorable relationship between expansion and tumor burden. Proteomics of patient serum collected at baseline and in the first month after CAR-T therapy revealed higher markers of endothelial dysfunction, inflammatory cytokines, macrophage activation, and T cell suppression in the aplastic phenotype group. Prolonged neutrophil aplasia thus occurs in patients with systemic immune dysregulation at baseline with subsequently impaired CAR-T expansion and myeloid-related inflammatory changes. The association between neutrophil recovery and survival outcomes highlights critical interactions between host hematopoiesis and the immune state stimulated by CAR-T infusion.
Impact Factor
Scopus SNIP
Altmetric
13.600
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Cytokine Release Syndrome; Stem-cell Boost; B-cell; Infectious Complications; Axicabtagene Ciloleucel; Interferon-gamma; Responses; Promotes; Interleukin-15; Inflammation
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 2375-2548
e-ISSN 2375-2548
Zeitschrift Science Advances
Quellenangaben Band: 9, Heft: 38, Seiten: , Artikelnummer: eadg3919 Supplement: ,
Verlag American Association for the Advancement of Science (AAAS)
Verlagsort Washington, DC [u.a.]
Begutachtungsstatus Peer reviewed
Institut(e) CF Metabolomics & Proteomics (CF-MPC)
POF Topic(s) 30203 - Molecular Targets and Therapies
PSP-Element(e) A-630700-001
Förderungen Bavarian Cancer Research Center (BZKF)
ElseKroner-Fresenius Stiftung
Wilhelm-Sander Stiftung
Bavarian Elite Graduate Training Network
DFG
Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
Bruno & Helene Joster Foundation
Gilead Research Scholar Program
Else Kroner Forschungskolleg (EKFK) within the Munich Clinician Scientist Program (MCSP)
School of Oncology of the German Cancer Consortium (DKTK)
DOI 10.1126/sciadv.adg3919
WOS ID 001071484100004
Scopus ID 85172097273
PubMed ID 37738350
Erfassungsdatum 2023-10-18
[➜Korrektur melden]